Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTXQ BioRestorative Therapies	$1.84 +0.6%	$1.56	$0.00 ▼ $0.06	$3.02B	102.36	62.17 million shs	182,026 shs
GH Guardant Health	$67.42 +4.6%	$51.69	$20.14 ▼ $67.51	$8.41B	1.43	2.82 million shs	2.86 million shs
HIMS Hims & Hers Health	$42.36 -4.0%	$49.98	$13.47 ▼ $72.98	$9.57B	2.08	29.95 million shs	16.08 million shs
RDNT RadNet	$71.76 0.0%	$59.87	$45.00 ▼ $93.65	$5.52B	1.43	1.05 million shs	627,715 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTXQ BioRestorative Therapies	+0.60%	+20.26%	+24.32%	+4.84%	+7.60%
GH Guardant Health	0.00%	+9.80%	+64.52%	+65.45%	+157.33%
HIMS Hims & Hers Health	0.00%	-4.87%	-35.99%	-25.34%	+189.34%
RDNT RadNet	0.00%	+2.37%	+31.12%	+24.20%	+9.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BRTXQ BioRestorative Therapies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	3.2556 of 5 stars	1.5	2.0	0.0	4.4	3.5	2.5	0.6
HIMS Hims & Hers Health	3.2229 of 5 stars	2.0	3.0	0.0	0.0	2.5	3.3	3.1
RDNT RadNet	3.2144 of 5 stars	1.6	2.0	0.0	4.6	4.1	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRTXQ BioRestorative Therapies	0.00	N/A	N/A	N/A
GH Guardant Health	3.06	Buy	$57.50	-14.71% Downside
HIMS Hims & Hers Health	1.92	Reduce	$38.92	-8.13% Downside
RDNT RadNet	3.25	Buy	$71.60	-0.22% Downside

Current Analyst Ratings Breakdown

Latest BRTXQ, HIMS, GH, and RDNT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	HIMS Hims & Hers Health	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/18/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$48.00 ➝ $37.00
8/18/2025	RDNT RadNet	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	RDNT RadNet	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy	$66.00 ➝ $75.00
8/11/2025	RDNT RadNet	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Overweight
8/5/2025	HIMS Hims & Hers Health	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
7/31/2025	GH Guardant Health	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$57.00 ➝ $60.00
7/31/2025	GH Guardant Health	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$59.00 ➝ $61.00
7/17/2025	HIMS Hims & Hers Health	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$45.00 ➝ $48.00
7/14/2025	GH Guardant Health	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/10/2025	RDNT RadNet	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$74.00

(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRTXQ BioRestorative Therapies	$110K	27,426.47	N/A	N/A	($0.68) per share	-2.71
GH Guardant Health	$739.02M	11.38	N/A	N/A	($2.45) per share	-27.52
HIMS Hims & Hers Health	$1.48B	6.48	$0.35 per share	120.26	$2.49 per share	17.01
RDNT RadNet	$1.83B	3.02	$3.48 per share	20.60	$15.33 per share	4.68

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRTXQ BioRestorative Therapies	-$12.52M	-$1.07	N/A	∞	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	-$436.37M	-$3.35	N/A	N/A	N/A	-49.93%	N/A	-28.95%	11/5/2025 (Estimated)
HIMS Hims & Hers Health	$126.04M	$0.80	52.95	81.46	2.86	9.63%	26.26%	13.06%	11/3/2025 (Estimated)
RDNT RadNet	$2.79M	-$0.20	N/A	135.40	N/A	-0.78%	2.41%	0.82%	11/10/2025 (Estimated)

Latest BRTXQ, HIMS, GH, and RDNT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2025	Q2 2025	RDNT RadNet	$0.17	$0.31	+$0.14	$0.43	$488.06 million	$498.23 million
8/4/2025	Q2 2025	HIMS Hims & Hers Health	$0.18	$0.17	-$0.01	$0.17	$550.06 million	$544.83 million
7/30/2025	Q2 2025	GH Guardant Health	-$0.52	-$0.44	+$0.08	-$0.80	$211.19 million	$232.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRTXQ BioRestorative Therapies	N/A	N/A	N/A	N/A	N/A
GH Guardant Health	N/A	N/A	N/A	N/A	N/A
HIMS Hims & Hers Health	N/A	N/A	N/A	N/A	N/A
RDNT RadNet	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRTXQ BioRestorative Therapies	N/A	N/A	N/A
GH Guardant Health	N/A	3.71	3.35
HIMS Hims & Hers Health	1.72	4.98	4.46
RDNT RadNet	0.91	2.00	2.00

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRTXQ BioRestorative Therapies	N/A
GH Guardant Health	92.60%
HIMS Hims & Hers Health	63.52%
RDNT RadNet	77.90%

Insider Ownership

Company	Insider Ownership
BRTXQ BioRestorative Therapies	12.20%
GH Guardant Health	6.10%
HIMS Hims & Hers Health	13.71%
RDNT RadNet	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRTXQ BioRestorative Therapies	7	1.64 billion	N/A	Not Optionable
GH Guardant Health	1,790	124.71 million	117.10 million	Not Optionable
HIMS Hims & Hers Health	1,637	226.02 million	195.03 million	Optionable
RDNT RadNet	8,970	76.92 million	72.61 million	Optionable

BRTXQ, HIMS, GH, and RDNT Headlines

Recent News About These Companies

AlphaQuest LLC Increases Position in RadNet, Inc. $RDNT

3 hours ago | marketbeat.com

RadNet, Inc. (NASDAQ:RDNT) Receives Consensus Recommendation of "Buy" from Brokerages

4 hours ago | marketbeat.com

RadNet (NASDAQ:RDNT) COO Sells $355,500.00 in Stock

August 30 at 7:18 AM | insidertrades.com

Hsbc Holdings PLC Sells 29,653 Shares of RadNet, Inc. $RDNT

August 30 at 4:14 AM | marketbeat.com

RadNet, Inc. $RDNT Holdings Lowered by Alpha Wave Global LP

August 28 at 8:37 AM | marketbeat.com

Wellington Management Group LLP Acquires 7,872 Shares of RadNet, Inc. $RDNT

August 28 at 4:23 AM | marketbeat.com

Raymond James Financial Inc. Purchases 19,311 Shares of RadNet, Inc. $RDNT

August 28 at 4:00 AM | marketbeat.com

Coulda, Woulda, Shoulda: Are These 5 Stocks Too Overvalued to Buy Now?

August 27, 2025 | kiplinger.comK

RadNet, Inc. $RDNT Shares Sold by Axiom Investors LLC DE

August 26, 2025 | marketbeat.com

EntryPoint Capital LLC Makes New $206,000 Investment in RadNet, Inc. $RDNT

August 26, 2025 | marketbeat.com

T. Rowe Price Investment Management Inc. Grows Position in RadNet, Inc. $RDNT

August 25, 2025 | marketbeat.com

Advantage Alpha Capital Partners LP Has $3.71 Million Stock Holdings in RadNet, Inc. $RDNT

August 24, 2025 | marketbeat.com

RadNet (NASDAQ:RDNT) Insider Ranjan Jayanathan Sells 65,598 Shares

August 24, 2025 | americanbankingnews.com

Russell Investments Group Ltd. Purchases 13,147 Shares of RadNet, Inc. $RDNT

August 24, 2025 | marketbeat.com

RadNet (NASDAQ:RDNT) Upgraded at Zacks Research

August 22, 2025 | marketbeat.com

Cornelis Wesdorp Sells 1,500 Shares of RadNet (NASDAQ:RDNT) Stock

August 22, 2025 | insidertrades.com

RadNet, Inc. $RDNT Shares Acquired by Northwest & Ethical Investments L.P.

August 22, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Sells 26,199 Shares of RadNet, Inc. $RDNT

August 22, 2025 | marketbeat.com

American Century Companies Inc. Acquires 1,063,516 Shares of RadNet, Inc. $RDNT

August 21, 2025 | marketbeat.com

RadNet, Inc. $RDNT Shares Acquired by LPL Financial LLC

August 21, 2025 | marketbeat.com

Analyzing Astrana Health (NASDAQ:ASTH) & RadNet (NASDAQ:RDNT)

August 21, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BRTXQ, HIMS, GH, and RDNT Company Descriptions

BioRestorative Therapies OTCMKTS:BRTXQ

$1.84 +0.01 (+0.60%)

As of 08/29/2025

BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.

Guardant Health NASDAQ:GH

$67.42 +2.95 (+4.58%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$67.32 -0.10 (-0.15%)

As of 08/29/2025 07:59 PM Eastern

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.

Hims & Hers Health NYSE:HIMS

$42.36 -1.76 (-3.99%)

Closing price 08/29/2025 03:59 PM Eastern

Extended Trading

$42.58 +0.23 (+0.53%)

As of 08/29/2025 08:00 PM Eastern

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

RadNet NASDAQ:RDNT

$71.76 -0.03 (-0.04%)

Closing price 08/29/2025 04:00 PM Eastern

Extended Trading

$70.96 -0.80 (-1.11%)

As of 08/29/2025 05:53 PM Eastern

RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems that distribute, display, store, and retrieve digital images; offers picture archiving communications systems and related services; and develops and deploys AI suites to enhance radiologist interpretation of breast, lung, and prostate images, as well as AI solutions for prostate cancer screening. RadNet, Inc. was founded in 1981 and is headquartered in Los Angeles, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time